Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced us of pancreatic cancer neovasculature in a genetically engineered mouse model: Potential for earlier detection

Radiology

Volumn 274, Issue 3, 2015, Pages 790-799

  Pysz, Marybeth A ^a,e   Machtaler, Steven B ^a   Seeley, E Scott ^b   Lee, John J ^a   Brentnall, Teresa A ^c   Rosenberg, Jarrett ^a   Tranquart, Franãois ^d   Willmann, Jürgen K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Bracco Suisse SA   (Switzerland)

^e Stemcentrx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; VASCULOTROPIN RECEPTOR 2;

ANIMAL; CHEMISTRY; DISEASE MODEL; EARLY CANCER DIAGNOSIS; ECHOGRAPHY; MICROBUBBLE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; MICE; MICE, TRANSGENIC; MICROBUBBLES; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84924303302     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140568     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts and Figures 2012. http:/ /www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed September 25, 2014
2. Xu Q, Zhang TP, Zhao YP. Advances in early diagnosis and therapy of pancreatic cancer. Hepatobiliary Pancreat Dis Int 2011;10(2): 128-135
3. Majumder S, Chubineh S, Birk J. Pancreatic cancer: An endoscopic perspective. Expert Rev Gastroenterol Hepatol 2012;6(1): 95- 103; quiz 104
4. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10(1): 88-95
5. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: A retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007;102(10): 2157-2163
6. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56(10): 1460-1469
7. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011;106(5): 946-954
8. Brentnall TA. Pancreatic cancer surveillance: learning as we go. Am J Gastroenterol 2011;106(5): 955-956
9. Shrikhande SV, Barreto SG, Goel M, Arya S. Multimodality imaging of pancreatic ductal adenocarcinoma: A review of the literature. HPB (Oxford) 2012;14(10): 658-668
10. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58(10): 1410-1418
11. Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: A prospective controlled study. Lancet 2000;356(9225): 190-193
12. Topazian M, Enders F, Kimmey M, et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007;66(1): 62-67
13. Kitano M, Kudo M, Yamao K, et al. Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography. Am J Gastroenterol 2012;107(2): 303-310
14. Kitano M, Kudo M, Sakamoto H, Komaki T. Endoscopic ultrasonography and contrastenhanced endoscopic ultrasonography. Pancreatology 2011;11(Suppl 2): 28-33
15. Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo M. Utility of contrastenhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol 2008;34(4): 525-532
16. Kersting S, Konopke R, Kersting F, et al. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas. Gastroenterology 2009;137(6): 1903-1911
17. Kersting S, Roth J, Bunk A. Transabdominal contrast-enhanced ultrasonography of pancreatic cancer. Pancreatology 2011;11(Suppl 2): 20-27
18. Kitano M, Kudo M, Maekawa K, et al. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004;53(6): 854-859
19. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6): 401-410
20. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144(5): 646-674
21. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62(3): 179-213
22. Folkman J. Angiogenesis. Annu Rev Med 2006;57: 1-18
23. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85(1): 27-34
24. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88(10): 2239-2245
25. Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002;25(2): 122-129
26. von Marschall Z, Cramer T, HÖcker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 2000;119(5): 1358-1372
27. Deshpande N, Ren Y, Foygel K, Rosenberg J, Willmann JK. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology 2011;258(3): 804-811
28. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17(24): 3112-3126
29. Pillai R, Marinelli ER, Fan H, et al. A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. Bioconjug Chem 2010;21(3): 556-562
30. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010;256(2): 519-527
31. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003;108(3): 336-341
32. Lindner JR, Song J, Xu F, et al. Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation 2000;102(22): 2745-2750
33. Pysz MA, Willmann JK. Targeted contrastenhanced ultrasound: An emerging technology in abdominal and pelvic imaging. Gastroenterology 2011;140(3): 785-790
34. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008;246(2): 508-518
35. Rissanen TT, Korpisalo P, Karvinen H, et al. High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC Cardiovasc Imaging 2008;1(1): 83-91
36. Deshpande N, Lutz AM, Ren Y, et al. Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US. Radiology 2012;262(1): 172-180
37. Brissova M, Shostak A, Shiota M, et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 2006;55(11): 2974-2985
38. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11): 1359-1370
39. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003;2(1): 8
40. Pochon S, Tardy I, Bussat P, et al. BR55: A lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010;45(2): 89-95
41. Mohammed A, Janakiram NB, Lightfoot S, Gali H, Vibhudutta A, Rao CV. Early detection and prevention of pancreatic cancer: use of genetically engineered mouse models and advanced imaging technologies. Curr Med Chem 2012;19(22): 3701-3713
42. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12(18): 5277-5287
43. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21(3): 418-429
44. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324(5933): 1457-1461
45. Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81(0): 126-134
46. Foygel K, Wang H, Machtaler S, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology 2013;145(4): 885-894, e3
47. Rognin NG, Campos R, Thiran JP, et al. A new approach for automatic motion compensation for improved estimation of perfusion quantification parameters in ultrasound imaging. Presented at the 8é Congrãs Franã§ais d'Acoustique. Tours, France, 2006.